AzurRx teams with Mayoly Spindler for Phase II drug trial

AzurRx BioPharma has partnered with Mayoly Spindler to begin a Phase II clinical trial to assess the safety and effectiveness of MS1819-SD for the treatment of patients who have exocrine pancreatic insufficiency (EPI) that is the result of chronic pancreatitis (CP).
"Today's announcement marks another step forward for AzurRx in helping to define the future for treating patients with exocrine pancreatic insufficiency,” AzurRx President and CEO Thijs Spoor said. “We are very pleased that our Phase II trial for MS1819 will be developed with such prestigious institutions. We believe that non-systemic therapies have the ability to make significant improvements in patients living with a variety of diseases where selective targeting of the therapy while specifically avoiding non-target organs will provide physicians around the world with meaningful improvements in patient care and will provide patients with innovative therapies designed to improve their quality of life."
There are an estimated 100,000 patients in the U.S. with EPI caused by CP.
“We are very pleased to begin this Phase IIa dose escalation trial. We strongly believe that such a product could have a significant improvement for the treatment of Exocrine Pancreatic Insufficiency,” Mayoly Spindler Laboratories CEO Stephane Thiroloix said.